This indicates that the development of small molecule targeted therapy against HER3 for use in HER2+ breast cancer needs to be directed away from stabilising the HER3 ATP binding pocket occupied conformer and rather towards stabilising the apo, inactive conformer. Here, ERBB2 is linked to breast carcinoma.